Could a pill and gel combo restore skin color in vitiligo?
NCT ID NCT07251595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called SHR0302, given as a tablet and a gel, for people with non-segmental vitiligo. The goal is to see if it can safely and effectively bring back skin color. About 176 adults aged 18 to 75 will take part, and some will receive a placebo to compare results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR0302 (a JAK inhibitor) taken as a tablet and applied as a gel
What this could lead to
If successful, this could offer a new treatment option to help restore skin color in people with vitiligo.
What could go wrong
This is an early Phase 2 trial with only 176 participants, so results may not apply to everyone. The drug may cause side effects or not work better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact